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student), anticonvulsants (2.8 Rx/student), adrenergics/amphet-
amine (2.4 Rx/student), antidepressants (2.3 Rx), and antipsy-
chotics (1.9 Rx/student). After controlling for demographics and
Medicaid enrollment status, ANCOVA indicated a signiﬁcant
SBHC intervention effect (Time*SBHC) for both monthly total
cost (F = 8.82, p = 0.003) and monthly mental health service cost
(F = 5.06, p = 0.025). CONCLUSION: The SBHC program that
provides mental health services for students did not decrease the
total Medicaid costs, instead, might increase the health quality
and health care accessibility for students with mental illnesses,
and this hypothesis should be examined in future research.
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OBJECTIVE: Case studies of behavioral carve-outs using
pre/post designs have found that they results in substantial
savings. Prior studies have not, however, examined the impact of
behavioral carve-outs on psychotropic medication usage and
costs. This study ﬁlls this gap. METHODS: Data came from
Medstat’s MarketScan claims database. The sample comprised
ten large employers with and without behavioral carve-outs. The
employers included about 1.4 million employees and their depen-
dents (about 890,000 were enrolled in carve-outs and 521,000
in non-carve-outs). A 2-part model was used to examine differ-
ences in the probably of use and the cost of services among users.
Total costs, inpatient, outpatient, and pharmaceutical costs were
examined. Independent variables included age, gender, diagno-
sis, region, plan type, and plan ﬁxed effects (to control for beneﬁt
design). Predicted expenditures were calculated using the smear-
ing technique. Inpatient and outpatient behavioral health claims
were identiﬁed by diagnosis. Psychotropic medications were
identiﬁed by the Redbook classiﬁcation system. RESULTS: There
was no difference in the probability of using pharmaceuticals or
the costs of pharmaceuticals among users between carve-outs
and non-carve-outs; although, predicted pharmaceutical expen-
ditures were lower for carve-outs ($4.80 versus $3.90). Carve-
outs had a lower probability of using inpatient care and
outpatient care. Carve-outs had higher costs for outpatient care
among users. The other differences were not statistically signiﬁ-
cant. Total predicted costs for carve-outs were about 28% lower
than for non-carve-outs. CONCLUSIONS: Behavioral carve-
outs have an incentive to shift usage away from mental health
ambulatory and hospital services and towards pharmaceuticals
because pharmaceutical usage is typically off the budget for
which they are held accountable. However, without very aggres-
sive utilization review, behavioral carve-outs may not have the
tools to inﬂuence pharmaceutical usage. This study ﬁnds that the
main effect of behavioral carve-outs is on the probably of inpa-
tient and outpatient behavioral health service usage.
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OBJECTIVES: The association between mental distress and
health risks, protective health behavior (in the form of preven-
tive health screenings) and health care costs was evaluated
among a commercially insured, adult population. METHODS:
The sample contains 10,055 employees age 18–75, which is a
sub-set of the managed care, health risk assessment database
[MCHRA]. The MCHRA data was collected from 2000–2003.
Bi-variable analysis, logistic regression and general linear regres-
sion models were performed to evaluate the association between
mental distress (low, medium and high) and health risks, health
lifestyle, preventive health screenings, and health care costs.
RESULTS: Using multi-variable logistic regression models, those
with high mental distress were signiﬁcantly more likely to smoke
(adjusted odds ratio [AOR] 1.26, p = 0.0027), drink alcohol
(AOR 5.75, p < 0.0001), more likely to not wear a helmet when
biking (AOR, 1.37, p = 0.0188), more likely to be overweight
(AOR 1.21, p = 0.0350), more likely to feel a loss of self esteem
(AOR 8.86, p < 0.0001), more likely to have lost interest in life
(AOR 12.23, p < 0.0001), more likely to report depression (AOR
16.53, p < 0.0001), more likely to have sleep problems (AOR,
3.81, p < .0001) and less likely to be tested for colon cancer
through FOBT tests (AOR 1.429, p = .0006) or colonoscopy
(AOR 1.93, p < 0.0001). Those with mental distress were more
likely to have higher health care costs overall (>$1,700; F =
20.08, p < 0.0001). Health care cost areas associated with
disease classiﬁcations showed those with higher distress had
higher costs related to treatment of mental disorders (>$140; F
= 44.50, p < 0 .0001), the nervous system (>$70; F = 3.34, p =
0.0675) and respiratory system (>$120; F = 15.36, p < 0.0001).
CONCLUSIONS: The ﬁndings indicate a strong association
between mental distress, health risk and lifestyle, and preventive
health behavior and health care costs.
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OBJECTIVES: Unlike many other health care organizations,
central Texas veterans do not have day supply limits on med-
ications. Thus, the potential for medication over-adherence
exists. The objectives of this study were to: 1) examine the adher-
ence rate (AR) and medication possession ratio (MPR) among
veterans taking antipsychotics; 2) determine whether over-
adherence (AR > 1 or MPR > 1) exists among veterans taking
antipsychotics; and 3) evaluate factors related to over-adherence.
METHODS: Data were extracted from the Central Texas Vet-
erans Health Care System (CTVHCS) from September 1995—
October 2002 for continuously enrolled adult outpatients who
were on monotherapy, and had at least two prescriptions within
a year. Demographic and relevant clinical information, including
age, gender, ethnicity, psychiatric diagnoses, and antipsychotic
prescription medication information were collected. Subjects
were followed up to 12 months. RESULTS: Among the eligible
patients (N = 3252), the mean AR was 1.56 (sd = 2.58) and MPR
was 1.23 (sd = 0.75). Over one-half (54.4%) of the subjects were
over-adherent with ARs and MPRs > 1. For those over-adherent
patients, the mean AR was 2.38 (sd = 3.27) and MPR was 1.70
(sd = 0.71). Multiple logistic analyses revealed that schizophrenic
patients (OR = 1.241, p = 0.0085) were signiﬁcantly more likely
to be over-adherent (MPR > 1), while nonwhite (OR = 0.617, p
< 0.0001), depressed patients (OR = 0.801, p = 0.0085) and
atypical users (OR = 0.620, p < 0.0001) were signiﬁcantly less
likely to be over-adherent. A second logistic analysis to assess
individual antipsychotic agents showed that, compared to
haloperidol, quetiapine users (OR = 2.309, p = 0.0073) were sig-
niﬁcantly more likely to be over-adherent, and olanzapine (OR
282 Abstracts
= 0.557, p < 0.0001) users were signiﬁcantly less likely to be
over-adherent. CONCLUSION: Over one-half of central Texas
veterans were over-adherent with their antipsychotic therapy.
Further studies are warranted to determine the impact of exces-
sive medication possession on patient outcomes as well as the
economic impact on the VA system.
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OBJECTIVE: Pemoline, a CNS stimulant, is approved for Atten-
tion Deﬁcit and Hyperactivity Disorder (ADHD). In practice, it’s
additionally used to treat narcolepsy and MS-related fatigue.
Because pemoline was associated with acute liver failure, FDA
relabeled its use as ‘second-line’ therapy (SLT) for ADHD in
1996. This retrospective observational study examines longitu-
dinal prescription records suggestive of ﬁrst or second-line use
to describe apparent compliance with relabeling and factors
associated with second-line use. METHODS: Prescription claims
from a continuously-enrolled population (September 1, 2000—
September 30, 2002) from AdvancePCS pharmacy beneﬁt
manager (PBM) were evaluated for patients with 1 or more
pemoline claims. Patients were categorized using pemoline as
SLT or ‘ﬁrst-line’ therapy (FLT) depending on presence/absence
of other CNS stimulant prescriptions 90 days prior to the ﬁrst
pemoline claim. Chi-square compared SLT and FLT patients with
regard to age, gender and prescribing physician specialty.
RESULTS: Of 50M covered lives, 2320 had pemoline claims:
51% male, 34% age 0–19 years. 22% used pemoline as SLT
(95% CI: 19%–24%). Children <20 years were more likely to
use pemoline as SLT (40%) than adults >19 years (14%) (p <
0.001). Across all ages, males were more likely to use pemoline
as SLT (27%) than females (17%) (p < 0.001). Physician spe-
cialty was associated with SLT (p < 0.001): pediatrics (43%),
psychiatry (32%), primary care (22%), and neurology (5%).
CONCLUSIONS: Most patients in a large PBM appear to use
pemoline without antecedent prescriptions for other CNS stim-
ulants, a prescribing pattern inconsistent with FDA-approved
SLT labeling. Although ADHD summertime “drug holidays”
>90 days may have inﬂated estimates of FLT that was actually
SLT, children had higher levels of SLT than adults. FDA’s label-
ing action may have affected approved ADHD usage (pre-
dominantly male pediatric patients) more than off-label
narcolepsy/MS usage (older neurology patients). These results in
a large patient population are consistent with earlier, smaller
studies.
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OBJECTIVES: The purpose of this study was to examine trends
in antipsychotic use in children and adolescents enrolled in three
Medicaid programs (a Midwestern [MM], Southern [SM], and
Western [WM] state) or a national private managed-care orga-
nization (MCO). METHODS: Antipsychotic prevalence was
deﬁned as the number of individuals under the age of 20 years
with at least one prescription claim for an antipsychotic agent,
regardless of subclass, per 1000 enrolled children and adoles-
cents. Total, antipsychotic subclass, age-speciﬁc, and gender-
speciﬁc prevalence rates of antipsychotic use from 1996 to 2001
were estimated. Time trends of antipsychotic prevalence esti-
mates were assessed. RESULTS: From 1996 to 2001, the preva-
lence of total antipsychotic use increased in each insurance
program (MM: +9.6 per 1000, odds ratio [OR] 1.24; SM: +9.2,
OR 1.19; WM: +2.4, OR 1.10; and, MCO: +2.0, OR 1.24). The
prevalence of typical antipsychotic use decreased (prevalence
ratios [2001 :1996] 0.29 to 0.72; OR 0.78 to 0.98), while the
prevalence of atypical antipsychotics dramatically increased
(prevalence ratios 5.99 to 19.73; OR 1.35 to 1.56). Across all
systems, the use of antipsychotics increased in children and ado-
lescents above the age of 5 years. Male and female antipsychotic
prevalence rates also increased. Antipsychotic usage was highest
in SM, followed by MM, WM, and MCO. CONCLUSIONS: In
all 4 programs, the prevalence of antipsychotic use in children
and adolescents increased signiﬁcantly from 1996 to 2001. This
is attributed to the increased use of atypical antipsychotics. Geo-
graphic and health system variations in antipsychotic prescribing
existed. Given the limited efﬁcacy and safety data with antipsy-
chotics in children and adolescents, this raises questions about
appropriate use and emphasizes the need for additional studies
of atypical antipsychotics in this population.
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OBJECTIVES: Determine whether there was a reduction in hos-
pital utilization following the implementation of an open access
policy for atypical antipsychotic medications for a publicly
funded drug program in Newfoundland and Labrador.
METHODS: The inpatient records of patients discharged from
hospital in 1995/96, 1998 and 2000 with an ICD-9 diagnosis of
schizophrenia were reviewed to determine the factors inﬂuenc-
ing total days hospitalization and readmission rates. Cox pro-
portional hazards models were used to identify factors associated
with LOS and logistic regression to determine early readmission.
RESULTS: Six hundred forty-ﬁve patients admitted in 3 study
years had 1,625 episodes of care totaling 47,098 days. The
number of hospital days increased by 1229 days in 1998 and
602 days in 2000 when compared to baseline (1995/96). The
study populations were similar with respect to sociodemographic
factors, psychiatric status and level of care provided. The pro-
portion of patients discharged on an atypical agent from an
index admission increased from 15% at baseline to 71% in the
ﬁnal year and the average LOS increased from 31 days to 39
days. Requiring electroconvulsive therapy (ECT), switching from
a conventional antipsychotic to an atypical agent during the
admission, requiring seclusion, or having thought disorder was
independently associated with a signiﬁcantly longer LOS.
Leaving against medical advice (AMA), or being suicidal on
admission decreased hospitalization. Fifty percent of the popu-
lation was readmitted in 215 days in 1995/96, 221 days in 1998,
and 223 days in 2000. Independent of the class of antipsychotic
prescribed on last discharge, leaving AMA and number of pre-
vious admissions signiﬁcantly increased the risk of readmission
within 1 year. CONCLUSIONS: The number of patients with
schizophrenia admitted to hospital decreased but the LOS
increased with no change in readmission rates. The expectations
that the associated higher costs would be offset by decreased hos-
pitalization for schizophrenia were not achieved.
